Specialty × MAC Jurisdiction Intelligence
OncologyCMS & MAC AlertsNGS (National Government Services) · Jurisdictions J6, JK
Every CMS transmittal, NGS (National Government Services) LCD revision, Federal Register notice, and OIG alert affecting Oncology billing teams in Connecticut, Illinois, Maine, Massachusetts, Minnesota, New Hampshire, New York, Rhode Island, Vermont, Wisconsin. Signal-scored and updated daily.
Active alerts
12
Critical / High
10
MAC jurisdiction
J6, JK
Highest-risk CPT
CPT 96413
Recent Oncology alerts under NGS (National Government Services)
10 of the 12 most recent Oncology reimbursement alerts are Critical/High-severity for NGS (National Government Services) (Jurisdictions J6, JK) billing teams. Each links to the source CMS/MAC document with the codes to review and the action to take.
- FDA Approval: RASONQUE (DARAXONRASIB) — Type 1 - New Molecular EntitySep 3, 2026
- FDA Approval: VOBRIG (LEUPROLIDE ACETATE) — Type 5 - New Formulation or New ManufacturerSep 3, 2026
- FDA Approval: LIBTAYO (CEMIPLIMAB-RWLC) — Type 1 - New Molecular EntitySep 3, 2026
- FDA Approval: BAVENCIO (AVELUMAB) — Type 1 - New Molecular EntitySep 3, 2026
- FDA Approval: UNLOXCYT (COSIBELIMAB) — Type 1 - New Molecular EntitySep 3, 2026
- FDA Approval: IMJUDO (TREMELIMUMAB) — Type 1 - New Molecular EntitySep 3, 2026
- FDA Approval: PENPULIMAB KCQX (PENPULIMAB) — Type 1 - New Molecular EntitySep 3, 2026
- FDA Approval: LOQTORZI (TORIPALIMAB-TPZI) — Type 1 - New Molecular EntitySep 3, 2026
- FDA Approval: TEVIMBRA (TISLELIZUMAB-JSGR) — Type 1 - New Molecular EntityAug 28, 2026
- FDA Approval: ZIIHERA (ZANIDATAMAB-HRII) — Type 1 - New Molecular EntityAug 28, 2026
- Proposed LCD DL40427: MolDX: Next-Generation Sequencing for Hematologic Malignancies and Suspected Hematologic Malignancies — NoridianNoridian · Aug 27, 2026
- Proposed LCD DL40435: MolDX: Transcriptional Biomarkers for Therapeutic Decision-Making in Renal Carcinoma — NoridianNoridian · Aug 27, 2026
Signal intelligence — Oncology × NGS (National Government Services)
Highest-risk CPT code
CPT 96413
Chemotherapy administration, intravenous push
View full CPT alert profileNGS (National Government Services) jurisdiction
J6, JK
Covers Connecticut, Illinois, Maine, Massachusetts, Minnesota, New Hampshire, New York, Rhode Island, Vermont, Wisconsin. Every oncology LCD revision, CMS transmittal, and Federal Register notice affecting these states is signal-scored and surfaced here daily.
View all 12 active alerts for Oncology under NGS (National Government Services)
Full alert text, action recommendations, effective date deadlines, MAC LCD links, and signal score rationale — updated daily.
About NGS (National Government Services) (Jurisdictions J6, JK)
NGS (National Government Services) is the Medicare Administrative Contractor responsible for processing Medicare Part A and Part B claims in Jurisdictions J6, JK, covering Connecticut, Illinois, Maine, Massachusetts, Minnesota, New Hampshire, New York, Rhode Island, Vermont, Wisconsin.NGS (National Government Services) issues Local Coverage Determinations (LCDs) that define coverage criteria, ICD-10-CM diagnosis code requirements, and CPT billing guidelines for Oncology procedures within its jurisdiction. CLV Intelligence monitors NGS (National Government Services)'s LCD publication feed, provider bulletin archives, and CMS contractor-specific transmittals daily.
Oncology alerts in other MAC jurisdictions
Get weekly Oncology alerts for NGS (National Government Services) — free
No credit card required. Unsubscribe any time.
Frequently asked
- What are the recent CMS updates for Oncology under NGS (National Government Services) MAC?
- According to CLV Intelligence data, updated September 3, 2026, there are currently 12 active CMS and MAC reimbursement policy alerts for Oncology under NGS (National Government Services) (Jurisdictions J6, JK). Of these, 10 are classified Critical or High priority based on signal scoring of source authority, effective-date urgency, and document type. Alerts originate from NGS (National Government Services) Local Coverage Determinations (LCDs), CMS transmittals, Federal Register proposed and final rules, and OIG compliance publications. CLV Intelligence monitors all NGS (National Government Services) publications daily and assigns a signal score (0–100) to surface the changes most likely to affect coding accuracy and reimbursement.
- How many active audit alerts exist for Oncology CPT codes under NGS (National Government Services)?
- According to CLV Intelligence data, 12 active reimbursement and policy alerts currently affect Oncology CPT codes monitored under NGS (National Government Services) (Jurisdictions J6, JK). 10 of these alerts carry a Critical or High signal score, indicating elevated compliance risk or near-term effective dates requiring timely coding review. The highest-risk CPT code currently flagged in the Oncology alert set is CPT 96413 (Chemotherapy administration, intravenous push), which appears in NGS (National Government Services) LCD and CMS billing guidance revisions. CLV Intelligence cross-references each alert against the HCPCS and CPT code sets to surface procedure-level exposure for Oncology billing teams.
- Which MAC jurisdiction covers Oncology billing for practices in the NGS (National Government Services) region?
- NGS (National Government Services) administers Medicare Part A and Part B claims for practices in Jurisdictions J6, JK. For Oncology providers, NGS (National Government Services) issues Local Coverage Determinations (LCDs) that define coverage criteria, billing requirements, ICD-10-CM diagnosis code ranges, and CPT procedure code guidelines applicable to Medicare claims in its jurisdiction. According to CLV Intelligence data, NGS (National Government Services) monitors 12 open Oncology alerts as of September 3, 2026. Practices in the NGS (National Government Services) jurisdiction should monitor LCD revisions at NGS (National Government Services)'s provider portal and through aggregated daily alerting services such as CLV Intelligence.
- Is CPT 96413 currently under CMS or MAC review for Oncology?
- According to CLV Intelligence data, CPT 96413 (Chemotherapy administration, intravenous push) is currently flagged as a high-signal procedure code within the Oncology alert set monitored under NGS (National Government Services) (Jurisdictions J6, JK). CMS and MAC contractors regularly review high-volume procedure codes for coverage criteria changes, NCCI edit revisions, medical necessity documentation requirements, and fee schedule adjustments. CLV Intelligence assigns CPT 96413 an elevated signal score based on the volume and recency of policy documents referencing this code. Oncology coding teams should review the latest NGS (National Government Services) LCD and CMS transmittals affecting CPT 96413 before claim submission to avoid denials or post-payment audits.